| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fatou Aw, Isabelle Goyer, Marie-Josée Raboisson, Christine Boutin, Philippe Major, Nagib Dahda. Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex. Pediatric cardiology. vol 38. issue 2. 2017-03-29. PMID:27878332. |
tuberous sclerosis complex is associated with benign tumors such as cardiac rhabdomyomas (rhm) caused by the disinhibition of the mammalian target of rapamycin (mtor) protein. |
2017-03-29 |
2023-08-13 |
Not clear |
| Rita Citraro, Antonio Leo, Andrew Constanti, Emilio Russo, Giovambattista De Sarr. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacological research. vol 107. 2017-03-20. PMID:27049136. |
excessive activation of mtor signaling, as a consequence of loss-of-function of genes encoding for tuberous sclerosis complex (tsc) 1 and 2, is linked to the development of cortical malformations and epilepsy. |
2017-03-20 |
2023-08-13 |
rat |
| Rita Citraro, Antonio Leo, Andrew Constanti, Emilio Russo, Giovambattista De Sarr. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacological research. vol 107. 2017-03-20. PMID:27049136. |
this mtor hyperactivation is associated with different epileptogenic conditions under the term of 'mtoropathies' such as tuberous sclerosis, focal cortical dysplasia, hemimegalencephaly and ganglioglioma. |
2017-03-20 |
2023-08-13 |
rat |
| Joanna Trelińska, Iwona Dachowska, Katarzyna Kotulska, Sergiusz Jóźwiak, Wojciech Fendler, Wojciech Młynarsk. Everolimus treatment among patients with tuberous sclerosis affects serum lipid profile. Pharmacological reports : PR. vol 68. issue 5. 2017-03-20. PMID:27423526. |
the purpose of the study was to evaluate lipid homeostasis before and after treatment of everolimus, the mammalian target of the rapamycin (mtor) inhibitor, among patients with tuberous sclerosis complex (tsc). |
2017-03-20 |
2023-08-13 |
Not clear |
| Patrick L Raber, Rosa A Sierra, Paul T Thevenot, Zhang Shuzhong, Dorota D Wyczechowska, Takumi Kumai, Esteban Celis, Paulo C Rodrigue. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. Oncotarget. vol 7. issue 14. 2017-02-10. PMID:27007050. |
silencing of the negative mtor regulator tuberous sclerosis complex-2 in t cells co-cultured with mdsc restored mtor activity, but resulted in t cell apoptosis. |
2017-02-10 |
2023-08-13 |
Not clear |
| Jasna Jancic, Vesna Duric, Nikola Ivancevic, Blazo Nikolic, John N van den Anker, Janko Samardzi. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC. Current medicinal chemistry. vol 23. issue 37. 2017-02-08. PMID:27739368. |
tuberous sclerosis complex (tsc) is a genetic disease which is considered to be a prototype of a dysregulated mtor signaling pathway. |
2017-02-08 |
2023-08-13 |
Not clear |
| L Y Pang, L P Zou, L L Huang, Y Gao, S F Ma, M N Zhang, Y Y Wan. [Rapamycin in the treatment of cardiac rhabdomyoma associated with tuberous sclerosis complex]. Zhonghua er ke za zhi = Chinese journal of pediatrics. vol 54. issue 6. 2017-01-30. PMID:27256228. |
to assess the efficacy and safety of mammalian target of rapamycin (mtor) inhibitor rapamycin in treatment of children with cardiac rhabdomyoma, associated with tuberous sclerosis complex (tsc). |
2017-01-30 |
2023-08-13 |
Not clear |
| Kristen D Starbuck, Richard D Drake, G Thomas Budd, Peter G Ros. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. Anticancer research. vol 36. issue 11. 2017-01-30. PMID:27793946. |
identification of mutations in the tuberous sclerosis 1 (tsc1) and tsc2 genes producing constitutive activation of the mammalian target of rapamycin (mtor) pathway presents an opportunity for targeted therapy. |
2017-01-30 |
2023-08-13 |
Not clear |
| Andrew R Tee, Julian R Sampson, Deb K Pal, Joseph M Batema. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Seminars in cell & developmental biology. vol 52. 2017-01-17. PMID:26849906. |
the role of mtor signalling in neurogenesis, insights from tuberous sclerosis complex. |
2017-01-17 |
2023-08-13 |
Not clear |
| Vinit V Patil, Miguel Guzman, Angela N Carter, Geetanjali Rathore, Daniel Yoshor, Daniel Curry, Angus Wilfong, Satish Agadi, John W Swann, Adekunle M Adesina, Meenakshi B Bhattacharjee, Anne E Anderso. Activation of extracellular regulated kinase and mechanistic target of rapamycin pathway in focal cortical dysplasia. Neuropathology : official journal of the Japanese Society of Neuropathology. vol 36. issue 2. 2017-01-09. PMID:26381727. |
moreover, extracellular regulated kinase (erk) has been shown to phosphorylate s6 at serine 235/236 (s(235/236) ) and tuberous sclerosis complex 2 (tsc2) at serine 664 (s(664) ) leading to hyperactive mtor signaling. |
2017-01-09 |
2023-08-13 |
Not clear |
| K Sadowski, K Kotulska, R A Schwartz, S Jóźwia. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review. Journal of the European Academy of Dermatology and Venereology : JEADV. vol 30. issue 4. 2016-12-27. PMID:26403211. |
systemic effects of treatment with mtor inhibitors in tuberous sclerosis complex: a comprehensive review. |
2016-12-27 |
2023-08-13 |
Not clear |
| K Sadowski, K Kotulska, R A Schwartz, S Jóźwia. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review. Journal of the European Academy of Dermatology and Venereology : JEADV. vol 30. issue 4. 2016-12-27. PMID:26403211. |
tuberous sclerosis complex (tsc) is a genetic multisystem disorder associated with constitutive overactivation of the mammalian target of rapamycin (mtor) pathway and characterized by development of benign tumours in various organs. |
2016-12-27 |
2023-08-13 |
Not clear |
| Anna Jeong, Michael Won. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy. Expert review of neurotherapeutics. vol 16. issue 4. 2016-12-23. PMID:26854692. |
tuberous sclerosis complex (tsc) is a multiorgan disorder caused by a defect in the mtor (mechanistic/mammalian target of rapamycin) pathway. |
2016-12-23 |
2023-08-13 |
Not clear |
| Cyndi R Morales, Dan L Li, Zully Pedrozo, Herman I May, Nan Jiang, Viktoriia Kyrychenko, Geoffrey W Cho, Soo Young Kim, Zhao V Wang, David Rotter, Beverly A Rothermel, Jay W Schneider, Sergio Lavandero, Thomas G Gillette, Joseph A Hil. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Science signaling. vol 9. issue 422. 2016-12-20. PMID:27048565. |
we determined that the abundance of tuberous sclerosis complex 2 (tsc2), an mtor inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class i hdacs were inhibited. |
2016-12-20 |
2023-08-13 |
mouse |
| H S Rugo, G N Hortobagyi, J Yao, M Pavel, A Ravaud, D Franz, F Ringeisen, J Gallo, N Rouyrre, O Anak, R Motze. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Annals of oncology : official journal of the European Society for Medical Oncology. vol 27. issue 3. 2016-12-13. PMID:26759276. |
everolimus, an oral mammalian target of rapamycin (mtor) inhibitor, is used to treat solid tumors and tuberous sclerosis complex (tsc). |
2016-12-13 |
2023-08-13 |
Not clear |
| Paolo Curatolo, Marit Bjørnvold, Patricia E Dill, José Carlos Ferreira, Martha Feucht, Christoph Hertzberg, Anna Jansen, Sergiusz Jóźwiak, J Christopher Kingswood, Katarzyna Kotulska, Alfons Macaya, Romina Moavero, Rima Nabbout, Bernard A Zonnenber. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Drugs. vol 76. issue 5. 2016-12-13. PMID:26927950. |
the role of mtor inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. |
2016-12-13 |
2023-08-13 |
Not clear |
| Andras Fogarasi, Liesbeth De Waele, Gabriella Bartalini, Sergiusz Jozwiak, Nicola Laforgia, Helene Verhelst, Borivoj Petrak, Jean-Michel Pedespan, Olaf Witt, Ramon Castellana, Stefania Crippa, Gabriella Gislimberti, Zsuzsanna Gyorso. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. BMC neurology. vol 16. 2016-12-13. PMID:27502586. |
everolimus, a mammalian target of rapamycin (mtor) inhibitor, has been shown to be effective and safe in the treatment of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc). |
2016-12-13 |
2023-08-13 |
Not clear |
| Lam Son Nguyen, Taiane Schneider, Marlène Rio, Sébastien Moutton, Karine Siquier-Pernet, Florine Verny, Nathalie Boddaert, Isabelle Desguerre, Arnold Munich, José Luis Rosa, Valérie Cormier-Daire, Laurence Colleau. A nonsense variant in HERC1 is associated with intellectual disability, megalencephaly, thick corpus callosum and cerebellar atrophy. European journal of human genetics : EJHG. vol 24. issue 3. 2016-10-31. PMID:26153217. |
herc1 is an ubiquitin ligase that interacts with tuberous sclerosis complex 2, an upstream negative regulator of the mtor pathway. |
2016-10-31 |
2023-08-13 |
Not clear |
| Ian Damerill, Kyle K Biggar, Majida Abu Shehab, Shawn Shun-Cheng Li, Thomas Jansson, Madhulika B Gupt. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition. Molecular endocrinology (Baltimore, Md.). vol 30. issue 2. 2016-10-31. PMID:26714229. |
conversely, we activated mtorc1 or mtorc1+mtorc2 by silencing endogenous mtor inhibitors (tuberous sclerosis complex 2/dep-domain-containing and mtor-interacting protein). |
2016-10-31 |
2023-08-13 |
Not clear |
| Fu-Zheng Wei, Ziyang Cao, Xi Wang, Hui Wang, Mu-Yan Cai, Tingting Li, Naoko Hattori, Donglai Wang, Yipeng Du, Boyan Song, Lin-Lin Cao, Changchun Shen, Lina Wang, Haiying Wang, Yang Yang, Dan Xie, Fan Wang, Toshikazu Ushijima, Ying Zhao, Wei-Guo Zh. Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy. vol 11. issue 12. 2016-10-31. PMID:26735435. |
downregulation of tsc2 (tuberous sclerosis 2) by ezh2 elicited mtor activation, which in turn modulated subsequent mtor pathway-related events, including inhibition of autophagy. |
2016-10-31 |
2023-08-13 |
human |